UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 22, 2010
Marina Biotech, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-13789 | | 11-2658569 |
| (State or other jurisdiction | | (Commission | | (I.R.S. Employer |
| of incorporation) | | File Number) | | Identification No.) |
| | |
3830 Monte Villa Parkway, Bothell, Washington | | 98021 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: 425-908-3600
N/A
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
Orphan Drug Status for CEQ508
On December 29, 2010, Marina Biotech, Inc. (the “Company”) issued a press release to announce that the U.S. Food and Drug Administration has granted orphan drug designation to the Company’s drug candidate CEQ508 for the treatment of Familial Adenomatous Polyposis. A copy of the press release is attached as Exhibit 99.1 hereto.
Amendment of Agreement with Par Pharmaceutical
On December 22, 2010, the Company entered into an amendment of that certain Asset Purchase Agreement, dated as of March 31, 2009, between Par Pharmaceutical, Inc. (“Par”) and the Company (the “Purchase Agreement”), pursuant to which the Company will receive from Par a lump-sum cash payment in the amount of $700,000 in lieu of profit sharing for five years on commercial sales of generic calcitonin-salmon nasal spray. The Company previously sold to Par all of its assets relating to generic calcitonin-salmon nasal spray pursuant to the Asset Purchase Agreement.
Item 9.01 Financial Statements and Exhibits.
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press release of Marina Biotech, Inc., dated December 29, 2010 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| | | | | | Marina Biotech, Inc. |
| | | |
| December 29, 2010 | | | | By: | | /S/ J. MICHAEL FRENCH |
| | | | | | Name: | | J. Michael French |
| | | | | | Title: | | President and CEO |
EXHIBIT INDEX
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Press release of Marina Biotech, Inc., dated December 29, 2010 |
